Syngene International Ltd

Syngene International Ltd announced the resignation of Mr. Kush Parmar from his position as Independent Director, effective July 29, 2026. Mr. Parmar will also step down from the Risk Management Committee and the Science and Technology Committee. The resignation is attributed to existing and increasing commitments in the USA, making it difficult to devote sufficient time to the company while residing outside India. The company expressed appreciation for his contributions. Mr. Parmar confirmed no other material reasons for his resignation.

Syngene International Ltd reported its Q1 FY27 results, with revenue from operations at ₹736 Cr, a 16% decrease year-on-year from ₹875 Cr in Q1 FY26. Operating EBITDA saw a significant drop of 56% to ₹91 Cr from ₹206 Cr. The company cited a lack of offtake from a major biologics client and forex hedge loss as primary reasons for the performance dip. Profit After Tax (PAT) before exceptional items was ₹11 Cr, down 99% from ₹87 Cr. The company announced strategic shifts with Kiran Mazumdar-Shaw taking on the role of Executive Chairperson and Siddharth Mittal as the new MD & CEO. They aim to focus on CDMO and AI-led services for sustainable growth. The company also announced board changes with Dr. Vijaya Chandru and Dr. Arun Chandavarkar appointed as Independent Directors, while Dr. Kush Parmar steps down. Syngene also signed an MoU with THSTI for clinical development and translational research.

Syngene International Ltd announced its un-audited financial results for the quarter ended June 30, 2026. The Board of Directors approved the standalone and consolidated financial results as per Indian Accounting Standards (Ind-AS). The results were presented following a board meeting held on July 29, 2026. Key financial metrics such as revenue, expenses, profit before tax, and earnings per share for the quarter are detailed in the filing, along with comparative figures from the previous year and preceding quarter. The company also provided information on its paid-up equity share capital and reserves.

Syngene International Ltd announced the outcome of its Board Meeting held on July 29, 2026. The Board approved the un-audited financial results (standalone and consolidated) for the quarter ended June 30, 2026, prepared as per Indian Accounting Standards (Ind-AS). The results, along with the Limited Review Reports, have been submitted. The meeting commenced at 10:00 am IST and concluded at 03:31 pm IST. The company also informed that the financial results will be available on its website.

Mirae Asset Mutual Fund has disclosed the sale of 861,450 shares in Syngene International Ltd on July 21, 2026. This transaction represents a 0.21% stake in the company. Following the sale, Mirae Asset Mutual Fund's holding in Syngene International has reduced to 3,260,491 shares, accounting for 0.81% of the total diluted share capital. The sale was conducted through the open market.

Syngene International Ltd announced that Mr. Surender Sharma, General Counsel and a member of the Executive Committee, will be leaving the company by mutual consent effective July 15, 2026. Mr. Sharma is departing to pursue other career opportunities. The company has provided the necessary details as per SEBI Listing Regulations. This change in senior managerial personnel is effective in the near future, allowing for a transition period.

Syngene International Ltd has announced a Board of Directors meeting scheduled for July 29, 2026. The primary agenda is to consider and approve the un-audited standalone and consolidated financial results for the quarter ending June 30, 2026. Concurrently, the company has closed its trading window for insiders from July 1, 2026, to July 31, 2026. An analyst and investor conference call is planned for July 30, 2026.

Syngene International Ltd announced that M/s. B S R & Co. LLP, the Statutory Auditors of its material subsidiary, Syngene Scientific Solutions Limited (SSSL), has resigned. The resignation is effective immediately. The auditors cited the need to align with the holding company's auditors due to mandatory rotation requirements under the Companies Act, 2013, as the primary reason for their decision. They have completed the audit for the period ending March 31, 2026, and issued their report on April 28, 2026. The company will file the necessary forms with the Registrar of Companies (ROC) in due course.

Syngene International Ltd has received an order dated May 14, 2026, from the Deputy Commissioner of Income-tax, giving effect to an order passed by the National Faceless Appeal Centre (NFAC) for Assessment Year 2014-15. The order follows an appeal filed by the company against an initial demand of ₹16,72,20,900, which was later increased to ₹33,69,27,800. The NFAC partly allowed the appeal, and the subsequent order grants a refund of ₹8,62,14,600, including interest. The company is analyzing the order and expects no material financial impact, with a decrease in contingent liability. The refund amount is yet to be received.

Syngene International Ltd has announced the resignation of Mr. Peter Bains from his positions as Managing Director & Chief Executive Officer (Key Managerial Personnel). His resignation is effective from the close of business hours on June 30, 2026. The company has submitted Mr. Bains' resignation letter as per SEBI Listing Regulations. Mr. Bains expressed his commitment to ensuring a smooth leadership transition and reflected on his tenure, expressing gratitude to the Board, colleagues, and stakeholders. The company will make this information available on its website.